Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells. (3rd July 2019)

• Record Type: Journal Article
• Authors: Lei, Hu; Tu, Yaoyao; Yang, Li; Jin, Jin; Luo, Hao; Xu, Hanzhang; Kang, Jingwu; Zhou, Li; Wu, Yingli
• Is Part Of: Cancer investigation. Volume 37:Number 6(2019)
• Page Start: 242
• Page End: 252
• Publication Date: 2019-07-03
• Subjects: Quinacrine -- BCR-ABL -- RNA polymerase I -- CML; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2019.1630633
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Drug resistance to TKIs and the existance of CML leukemia stem cells is an urgent problem. In this study, we demonstrate that quinacrine (QC) induces apoptosis in BCR-ABL positive CML and acute lymphoblastic leukemia (ALL) cells. Interestingly, QC inhibits the colony formation of primary CD34 + progenitor/stem leukemia cells from CML patients. QC targets RNA polymerase I, which produces ribosomal (r)RNA, involving in protein translation process. Also, QC treatment prolongs CML-like mice survival and inhibits K562 tumor growth in vivo . In conclusion, we demonstrate that QC depletes BCR-ABL protein and suppresses Ph-positive leukemia cells in vitro and in vivo .